PCM
RGLS

Pinz Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Pinz Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,230
Closed -$18K – 348
2021
Q2 		$18K Buy
+2,230
New +$24.9K 0.01% 382

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pinz Capital Management's RGLS Position: Q3 2021 in Review

Pinz Capital Management sold out of Regulus Therapeutics (RGLS) in Q3 2021, closing a stake of 2,230 shares — an estimated $18K sold.

Pinz Capital Management first reported a position in RGLS in Q2 2021 and held it in 1 quarter. The position peaked at $18K in Q2 2021. 41 funds tracked by Wall St. Rank hold RGLS as of Q3 2021.

  • Pinz Capital Management reported no remaining Regulus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 2,230 Regulus Therapeutics shares in Q3 2021, an estimated $18K.
  • Pinz Capital Management first reported a position in Regulus Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Regulus Therapeutics position peaked at $18K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.